What are the extrapyramidal side effects of typical and atypical antipsychotics, and how should they be prevented, assessed for risk, and managed?

Extrapyramidal Side Effects of Antipsychotics

Immediate Management Based on EPS Type

For acute dystonia, administer benztropine 1-2 mg IM/IV or diphenhydramine 12.5-25 mg IM/IV immediately, as this is a medical emergency that provides relief within minutes. 1

Acute Dystonia (Medical Emergency)

• Presents as sudden spastic muscle contractions affecting the neck (torticollis), eyes (oculogyric crisis), or torso, typically within the first 3-5 days of treatment or after dose increases 1, 2, 3
• Young males are at highest risk, particularly in the first few days of antipsychotic exposure 1, 2
• Laryngospasm can be life-threatening and requires immediate intervention 1

Treatment protocol:

• Benztropine 1-2 mg IM/IV provides rapid relief within minutes 1
• Alternative: Diphenhydramine 12.5-25 mg IM/IV if benztropine unavailable 1
• Continue anticholinergic therapy even after antipsychotic discontinuation to prevent delayed symptom emergence 2

Drug-Induced Parkinsonism

Follow this hierarchical approach: (1) reduce antipsychotic dose, (2) switch to olanzapine/quetiapine/clozapine, (3) add anticholinergics only if first two strategies fail. 1, 2

• Symptoms include bradykinesia, tremors, and rigidity that mimic idiopathic Parkinson's disease 1, 4
• Typically appears within the first 3 months of treatment 3
• Early diagnosis and rapid antipsychotic withdrawal improves recovery potential 1

Avoid routine anticholinergic prophylaxis as it adds unnecessary medication burden and side effects without clear benefit in most patients 2, 5

Akathisia (Most Difficult to Treat)

Akathisia is frequently misdiagnosed as psychotic agitation or anxiety, leading to inappropriate dose escalation that worsens the condition. 1, 2

• Presents as severe subjective restlessness with objective motor activity (pacing, inability to sit still) 1, 4, 3
• Appears days to weeks after antipsychotic initiation 3

Treatment algorithm:

1. Reduce antipsychotic dose first if clinically feasible 1, 3
2. Add lipophilic beta-blockers (propranolol or metoprolol) as most effective pharmacological treatment 1, 3
3. Consider benzodiazepines or anticholinergics as third-line options, though less consistently effective 1, 3

Tardive Dyskinesia (Long-Term Risk)

• Involuntary choreiform or athetoid movements, typically affecting orofacial region but can involve any body part 1, 2
• Occurs in approximately 5% of young patients per year on long-term antipsychotic therapy 1, 2
• Monitor every 3-6 months using standardized scales (e.g., AIMS) during chronic treatment 1, 4

Medication Selection to Minimize EPS Risk

Lowest EPS Risk (Preferred)

Olanzapine, quetiapine, and clozapine have the lowest EPS risk among all antipsychotics. 1, 2

• Clozapine has minimal EPS risk and may even alleviate parkinsonian symptoms, but requires weekly-to-monthly blood monitoring for agranulocytosis (1% risk) 2
• Quetiapine and olanzapine are excellent alternatives without hematologic monitoring requirements 1, 2

Dose-Dependent EPS Risk

Risperidone carries significant dose-dependent EPS risk:

• Above 2 mg/day in elderly/dementia patients 2
• Above 4-6 mg/day in general adult populations 1, 2
• Start at 2 mg/day for first-episode psychosis 2
• In pediatric populations, use particularly cautious dosing despite some controlled trials showing comparable EPS rates to placebo 2

Highest EPS Risk (Avoid When Possible)

High-potency typical antipsychotics (haloperidol, droperidol) produce significantly more EPS due to strong dopamine D2 receptor blockade 2, 4

• Low-potency agents (chlorpromazine) cause more sedation but fewer EPS 4, 6
• Maximum 4-6 mg haloperidol equivalent in first-episode psychosis to stay within EPS limits 2

Prevention Strategies

Regular monitoring for early EPS signs is the preferred prevention strategy rather than prophylactic anticholinergics. 1, 2

When to Consider Prophylactic Anticholinergics

Reserve prophylaxis only for truly high-risk situations: 2

• Young males with history of previous dystonic reactions
• Paranoid patients where compliance is a major concern
• Reevaluate need after 2 weeks, as many patients no longer require antiparkinsonian agents during long-term therapy 2, 5

Dosing Strategy

• Use the lowest effective antipsychotic dose 2, 3
• Avoid rapid dose escalation—increase only at 14-21 day intervals after initial titration if response inadequate 2
• Start conservatively in pediatric populations despite their sometimes comparable EPS rates to adults 2

Special Population Considerations

Pediatric Patients

• Children and adolescents are at higher risk for EPS than adults, particularly acute dystonia 1, 2, 4
• Young males represent the highest-risk demographic 1, 2
• Use particularly cautious dosing strategies 1

Elderly Patients

Exercise extreme caution with anticholinergics in older adults due to risk of oversedation, confusion, and paradoxical agitation 1, 2

• Risperidone EPS risk increases significantly above 2 mg/day in this population 2
• Start at 0.25 mg/day at bedtime, maximum 2-3 mg/day 2

Critical Anticholinergic Medication Cautions

Anticholinergics can cause delirium, drowsiness, and paradoxical agitation, particularly in vulnerable populations. 1, 2

Contraindications for Diphenhydramine

Avoid in patients with: 2

• Glaucoma
• Benign prostatic hypertrophy
• Ischemic heart disease
• Hypertension

Paradoxical Reactions

Anticholinergics can paradoxically exacerbate agitation in patients with anticholinergic or sympathomimetic drug ingestions 1, 2

Assessment Before Attributing Symptoms to Medication

Rule out alternative causes before diagnosing medication-induced EPS: 4

• Neurological disorders (Parkinson's disease, Huntington's disease)
• Metabolic disturbances
• Structural brain lesions
• Substance intoxication or withdrawal (particularly anticholinergic or sympathomimetic agents)
• Physical illnesses mimicking EPS

Other Medications That Cause EPS

Antiemetics carry EPS risk: 2

• Metoclopramide causes tardive dyskinesia in approximately 20% of patients using it longer than 12 weeks 2
• FDA warns against metoclopramide use exceeding 12 weeks due to potentially irreversible tardive dyskinesia risk 2
• Prochlorperazine also carries EPS risk 2
• Immediately withdraw metoclopramide upon reporting of EPS symptoms 2

Other non-antipsychotic agents associated with EPS: 7

• Certain antidepressants
• Lithium
• Various anticonvulsants
• Rarely, oral contraceptives

Common Pitfalls to Avoid

1. Misinterpreting akathisia as psychotic agitation and inappropriately increasing antipsychotic dose, which worsens the condition 1, 2

2. Using routine prophylactic anticholinergics in all patients rather than reserving for high-risk situations 1, 2, 5

3. Continuing anticholinergics long-term without attempting gradual withdrawal after 2-4 weeks 2, 5

4. Failing to document baseline movement examination before starting antipsychotics, making tardive dyskinesia detection difficult 2

5. Not attempting to induce emesis in overdose situations with phenothiazines, as dystonic reactions of head/neck can cause aspiration 6